Drugs for treating urinary schistosomiasis

Area of Science:

• Tropical Medicine
• Infectious Diseases
• Pharmacology

Background:

• Urinary schistosomiasis, caused by Schistosoma haematobium, leads to chronic inflammation and fibrosis.
• The condition affects the bladder, causing significant morbidity and long-term complications.
• Current treatment options require updated efficacy and safety evaluations.

Purpose of the Study:

• To evaluate the efficacy and safety of drugs used to treat urinary schistosomiasis.
• To summarize the evidence from randomized controlled trials (RCTs) on antischistosomal drugs.

Main Methods:

• Searched multiple databases (Cochrane, MEDLINE, EMBASE, LILACS) for RCTs up to May 2014.
• Included RCTs comparing antischistosomal drugs against placebo, no intervention, or each other.
• Extracted data on parasitological failure and egg count reduction, assessing risk of bias and evidence quality (GRADE).

Main Results:

• Praziquantel (40 mg/kg) significantly reduced egg excretion by approximately 60% compared to placebo (high-quality evidence).
• Mean egg counts decreased by over 95% with praziquantel treatment.
• Metrifonate showed marginal improvement over placebo, and combination therapies require further investigation due to inconsistent results.

Conclusions:

• Praziquantel (40 mg/kg) is the most studied and evidence-based drug for urinary schistosomiasis.
• Combination therapies (e.g., praziquantel with metrifonate or antimalarials like artesunate) show potential but need rigorous trials.
• Standardized outcome measures and adequately powered trials are crucial for evaluating new treatment strategies.